Amgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020
Amgen today announced new data from its oncology pipeline in lung cancer will be presented during the 2020 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer taking place virtually from Jan. 28-31, 2021 . Phase 2 data from the CodeBreaK 100 clinical study, evaluating investigational sotorasib in patients with KRAS G12C -mutated advanced non-small cell lung cancer …
Amgen (NASDAQ:AMGN) today announced new data from its oncology pipeline in lung cancer will be presented during the 2020 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer taking place virtually from Jan. 28-31, 2021 .
Georgia US Navy Veterans Mesothelioma Advocate Appeals to the Family a Navy Veteran with Mesothelioma to Call Attorney Erik Karst of Karst von Oiste-Get Honest Answers About Compensation-Not Lawyer Roulette We are appealing to the family of a Navy Veteran with mesotheliomain Georgia to get serious about compensation and to call attorney Erik Karst of Karst von Oiste anytime at 800-714-0303. ” Georgia US Navy Veterans Mesothelioma Advocate
ATLANTA, GEORGIA , USA, January 11, 2021 /EINPresswire.com/ The Georgia US Navy Veterans Mesothelioma Advocate says, We are appealing to the family of a Navy Veteran with recently diagnosed mesothelioma anywhere in Georgia to get serious about compensation for this rare form of cancer and to call attorney Erik Karst of Karst von Oiste at 800-714-0303. Financial compensation for a Navy Veteran with mesothelioma in Georgia might exceed a million dollars for a Veteran who spent three or four years in the navy. For a career Navy Veteran with
Capivasertib May Be Helpful Against Tumors With Rare AKT Mutation medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
MedCity News
Trial results add to uses for Exact Sciences test
The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy and those who won t. The latest trial results extend the test s reach.
Shares1
A clinical trial shows that a genomic test from diagnostics company Exact Sciences can help more women with early-stage breast cancer avoid chemotherapy.
The test, Oncotype DX, had already demonstrated its ability to predict whether chemotherapy would benefit women with breast cancer that has not spread to lymph nodes, known as node-negative breast cancer.
Dec 17, 2020
The annual meeting of the San Antonio Breast Cancer Symposium was held virtually this year from Dec. 8 to 11 and attracted participants from around the world, including medical oncologists, radiation oncologists, researchers, and other health care professionals. The conference highlighted recent advances in the risk, diagnosis, treatment, and prevention of breast cancer, with presentations focusing on emerging treatments in hard-to-treat patient populations, including patients with metastatic breast cancer.
As part of the RxPONDER study, Kevin Kalinsky, M.D., of the Glenn Family Breast Center at the Winship Cancer Institute of Emory University in Atlanta, and colleagues found that postmenopausal women with lymph node-positive early-stage breast cancer and a low recurrence score receive no additional benefit from chemotherapy.